Obesity Reviews , 25(11), e13817
Published Phase 2 data (NEJM, 2023) showed retatrutide achieving up to 24.2% body weight reduction over 48 weeks and significant hepatic fat reduction, supporting research into obesity, NAFLD/MASH, and insulin resistance models
I see too many researchers reduce training intensity during recomposition because they expect to feel weak and depleted
161 However, these problems have not been shown to have a clear causal relationship with GLP-1RA in the general population, and there is a lack of data specific to the MASLD population, especially in individuals without co-existing T2DM
Expanding options for patients Widening the pool of available options beyond injectables could help meet consumer demand more effectively
In participants with baseline BMI 35 who continued on 12 mg through 104 weeks of total treatment: average weight loss of 85.0 lb (30.3%)